Zydus Lifesciences bags USFDA approval for Silodosin capsules and Pregabalin capsules

12 Dec 2022 , 09:28 AM

The United States Food and Drug Administration (USFDA) has given Zydus Lifesciences Limited final approval to market Silodosin Capsules, 4 mg, and 8 mg. The company also received final approval to market Pregabalin Capsules in the following strengths: 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg.

Silodosin capsules are used to treat the signs and symptoms of an enlarged prostate gland, also known as benign prostate enlargement (benign prostatic hyperplasia or BPH).

Pregabalin capsules are used to treat pain caused by nerve damage caused by diabetes or shingles (herpes zoster). It is also used to treat nerve pain caused by spinal cord injury and pain in fibromyalgia patients.

According to IQVIA MAT Sep 2022 data, Silodosin capsules had annual sales of USD 14 million in the United States. While pregabalin capsules had annual sales of USD 242 million in the United States.

At around 9.36 AM, Zydus Lifesciences was trading at Rs408 up by 0.15% from its previous closing of Rs407.40 on the BSE. The scrip opened at Rs411.55 and touched intraday high and low of Rs411.55 and Rs404.60 respectively.

For feedback and suggestions, write to us at [e-mail]